Israeli biotech Tikcro inks immune checkpoint inhibitor deal
This article was originally published in Scrip
Executive Summary
Tikcro Technologies has inked a research and licensing deal with Yeda Research and Development, the technology transfer arm of Israel's Weizmann Institute of Science, for antibodies targeting cancer immune checkpoints.